New Data On Gilead's Covid-19 Drug Is Positive, but Inconclusive | Barron's
Gilead reports 3% revenue growth in Q1 2022
Gilead's COVID-19 antiviral Veklury blew past sales estimates in late 2021 as omicron surged, vaccinations lagged | Fierce Pharma
Gilead to Slice List Prices of Liver Drugs - WSJ
Gilead Will Donate Truvada to U.S. for H.I.V. Prevention - The New York Times
Gilead Advancing Access®: What to Know | Prism Health North Texas
Gilead's Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster - The New York Times
Study: To be cost-effective, Gilead's new HIV pill needs near-50% price cut
Gilead reports reduced mortality risk with remdesivir for Covid-19
Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back Reimbursement To 340B Providers :: Pink Sheet
PrEP's Still Too Costly For Many People At Risk For HIV : Shots - Health News : NPR
More evidence remdesivir helps some coronavirus patients | CNN
United States v. Gilead: The Fight for PrEP | Bill of Health
The drug company that shocked the world with its prices dodged $10 billion in taxes, report says - The Washington Post
Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine - Los Angeles Times
Gilead's Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline strikes back | Fierce Pharma
Gilead prices remdesivir at $2,340 per patient for developed countries
Gilead Revenue Soars on Hepatitis C Drug - The New York Times
Top Research Reports for JPMorgan, Gilead Sciences & CSX
Gilead's Truvada faces Teva generics assault amid Descovy switching campaign | Fierce Pharma
Gilead bags EU approval for next-generation HIV drug - PMLiVE
Federal government sues Gilead Sciences, alleging patent infringement on HIV drugs
Global shortage of key Covid drug leads to NHS rationing | Coronavirus | The Guardian
Gilead Sciences, Inc.
